HHS to invest in domestic production of essential medical supplies

President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Headline
A JAMA study published Aug. 20 found that nearly 63% of all U.S. drug production facilities from 2019 through 2024 were in counties where a weather disaster…
Headline
B. Braun Medical has voluntarily recalled two lots of Lactated Ringer’s Injection USP 1000 mL and 0.9% Sodium Chloride Injection USP 1000 mL IV fluids due to…
Headline
The White House Aug. 13 released an executive order directing the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness…
Headline
The Food and Drug Administration has identified a Class I recall of Draeger SafeStar and TwinStar Filters due to a risk of misleading carbon dioxide readings.…
Headline
The Food and Drug Administration Aug. 8 announced an end to the national shortage of sodium chloride 0.9% IV solutions products. The agency said it continues…
Headline
The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by increasing regulatory…